{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/622b8f5080a3a00013890f23/6650f0d8f749480012d902e7?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Tuesday, May 28, 2024","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/622b8f5080a3a00013890f23/1716580517640-bc6e6bec4c113a7e30f42526c11c8f13.jpeg?height=200","description":"<p>Novo Nordisk reports that its GLP-1 drug Ozempic could help treat kidney disease.&nbsp;An advisory panel recommends the FDA approve Guardant Health’s colon cancer blood test.&nbsp;And Louisiana lawmakers vote to reclassify abortion pills as controlled dangerous substances.&nbsp;That’s coming up on today’s episode of Gist Healthcare Daily.&nbsp;</p>","author_name":"Gist Healthcare Daily"}